Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$28.10M+174.34%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Xingjuan Chao
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 327
- Beta
- 0.81
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 12.35
Financials
Revenue
$28.10M+174.3%Net Income
$-19.27MEBITDA
$-18.63MFree Cash Flow
$-13.79MEPS (diluted)
$-0.51Shares Outstanding (diluted)
38.03M+63.1%Operating Expenses
$45.92MCash & Debt
$129.26MRevenue by Segment (annual)
$89.06MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $89.06M | $-53.41M | $-1.46 |
| 2024 | $65.44M | $-40.45M | $-1.13 |
| 2023 | $45.23M | $-29.46M | $-1.26 |
| 2022 | $25.92M | $-37.16M | $-1.59 |
Valuation
CBLLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-65.12%Social Signal Score
Mentions (5)
- Newsmarketbeat.com·54d ago·Neutral
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
View source ↗ - Newsseekingalpha.com·56d ago·Positive
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·56d ago·Neutral
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·56d ago·Negative
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
CeriBell Q2 Earnings Call Highlights CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.50 per share
Typical surprise +5.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.51 vs $-0.47miss
- Mon, May 11$-0.52 vs $-0.39miss
- Tue, Feb 24$-0.36 vs $-0.43beat
- Tue, Nov 4$-0.37 vs $-0.43beat
- Tue, Aug 5$-0.38 vs $-0.40beat
- Thu, May 8$-0.36 vs $-0.43beat
Estimates and results for CBLL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CBLL officers and directors.
- Bought
- —
- Sold
- $11.0m
0 trades
35 trades
- Woo Raymondsold
- Chao Xingjuansold
- Blumberg Scottsold
- Foehr Davidsold
- Foehr Davidsold
- Woo Raymondsold
- Chao Xingjuansold
- Blumberg Scottsold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CBLL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.